On October 22, 2024, Panbela Therapeutics, Inc. entered into a material definitive agreement with Nant Capital, LLC, issuing a Senior Convertible Promissory Tranche A Note for $2,850,000 and agreeing to issue a Tranche B Note for $9,150,000 by November 15, 2024. These notes, accruing interest at 8.00% plus the Monthly SOFR Rate, are convertible into common stock at $0.37 per share, subject to a 33.33% beneficial ownership cap for the investor. The proceeds are intended for general corporate purposes and repayment of existing debts. The company's subsidiaries, Cancer Prevention Pharmaceuticals, Inc. and Panbela Research, Inc., have guaranteed the obligations under the agreement. The securities, unregistered under the Securities Act, rely on an exemption for private placements. This financial move, detailed in a Form 8-K filed with the SEC, is part of a broader prospectus supplement filed to update information from a June 16, 2023, prospectus. Panbela Therapeutics' common stock is quoted on the OTCQB under the symbol 'PBLA', with a last reported sales price of $0.34 per share as of October 28, 2024.

On October 22, 2024, Panbela Therapeutics, Inc. entered into a material definitive agreement with Nant Capital, LLC, issuing a Senior Convertible Promissory Tranche A Note for $2,850,000 and agreeing to issue a Tranche B Note for $9,150,000 by November 15, 2024. These notes, accruing interest at 8.00% plus the Monthly SOFR Rate, are convertible into common stock at $0.37 per share, subject to a 33.33% beneficial ownership cap for the investor. The proceeds are intended for general corporate purposes and repayment of existing debts. The company's subsidiaries, Cancer Prevention Pharmaceuticals, Inc. and Panbela Research, Inc., have guaranteed the obligations under the agreement. The securities, unregistered under the Securities Act, rely on an exemption for private placements. This financial move, detailed in a Form 8-K filed with the SEC, is part of a broader prospectus supplement filed to update information from a June 16, 2023, prospectus. Panbela Therapeutics' common stock is quoted on the OTCQB under the symbol 'PBLA', with a last reported sales price of $0.34 per share as of October 28, 2024.